BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease

Neurobiology of Aging

Volumn 34, Issue 11, 2013, Pages 2457-2464

  Lim, Yen Ying ^a   Villemagne, Victor L ^a,b   Laws, Simon M ^c,d,e   Ames, David ^a,f   Pietrzak, Robert H ^g   Ellis, Kathryn A ^a,f   Harrington, Karra D ^a   Bourgeat, Pierrick ^h   Salvado, Olivier ^h   Darby, David ^a   Snyder, Peter J ⁱ   Bush, Ashley I ^a   Martins, Ralph N ^c,d   Masters, Colin L ^a   Rowe, Christopher C ^a,b   Nathan, Pradeep J ^j,k,l   Maruff, Paul ^a,m  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e Co operative Research Centre ^*  (Australia)

^f NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CSIRO   (Australia)

ⁱ BROWN UNIVERSITY   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l MONASH UNIVERSITY   (Australia)

^m CogState Ltd ^*  (Australia)

more..

Author keywords

A accumulation; BDNF Val66Met; Beta Amyloid; Cognitive decline; Healthy older adults; Hippocampal atrophy; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; VALINE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUSTRALIA; BRAIN ATROPHY; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LANGUAGE DISABILITY; MALE; MEMORY DISORDER; NORMAL HUMAN; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AΒ ACCUMULATION; BDNF VAL66MET; BETA-AMYLOID; COGNITIVE DECLINE; HEALTHY OLDER ADULTS; HIPPOCAMPAL ATROPHY; PRECLINICAL ALZHEIMER'S DISEASE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; AUSTRALIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, EPISODIC; METHIONINE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; THIAZOLES; VALINE;

EID: 84881546095     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.05.006     Document Type: Article

References (36)

1. Albert M.S., Blacker D., Moss M.B., Tanzi R., McArdle J.J. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology 2007, 21:158-169.
2. Baker L.D., Frank L.L., Foster-Schubert K., Green P.S., Wilkinson C.W., McTiernan A., Plymate S.R., Fishel M.A., Stennis Watson G., Cholerton B.A., Duncan G.E., Mehta P.D., Craft S. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch. Neurol. 2010, 67:71-79.
3. Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N.Engl. J. Med. 2012, 367:795-804. Dominantly Inherited Alzheimer Network.
4. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Genet. 2007, 39:17-23.
5. Bicalho M.A.C., Pimenta F.A., Bastos-Rodrigues L., de Oliveira Hansen E., Neves S.C., Melo M., Rosa D.V., de Souza R.P., de Miranda D.M., deMoraes E.N., Romano-Silva M.A., de Marco L. Sociodemographic characteristics, clinical factors, and genetic polymorphisms associated with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2012, 28:640-646.
6. Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., Zubieta J.K. BDNF Val66Metallele is associated with reduced hippocampal volume in healthy subjects. Biol. Psychiatry 2006, 59:812-815.
7. Caccamo A., Maldonado M.A., Bokov A.F., Majumder S., Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2010, 107:22687-22692.
8. Chételat G., Villemagne V.L., Pike K.E., Ellis K.A., Bourgeat P., Jones G., O'Keefe G.J., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C., Rowe C.C. Independent contribution of temporal β-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2010, 134:798-807. AIBL Research Group.
9. Chételat G., Villemagne V.L., Villain N., Jones G., Ellis K.A., Ames D., Martins R.N., Masters C.L., Rowe C. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012, 78:477-484. AIBL Research Group.
10. Connor B., Young D., Yan Q., Faull R.L., Synek B., Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Mol. Brain Res. 1997, 49:71-81.
11. Cotman C.W., Berchtold N.C., Christie L.A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007, 30:464-472.
12. Dennis N.A., Cabeza R., Need A.C., Waters-Metenier S., Goldstein D.B., LaBar K.S. Brain-derived neurotrophic factor val66met polymorphism and hippocampal activation during episodic encoding and retrieval tasks. Hippocampus 2011, 21:980-989.
13. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
14. Ellis K.A., Bush A.I., Darby D., De Fazio D., Foster J., Hudson P., Lautenschlager N., Lenzo N., Martins R.N., Maruff P., Masters C., Milner A., Pike K., Rowe C., Savage G., Szoeke C., Taddei K., Villemagne V., Woodward M., Ames D. The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatr. 2009, 21:672-687. AIBL Rsearch Group.
15. Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-β and memory loss. Future Neurol. 2011, 6:627-639.
16. Fukumoto N., Fujii T., Combarros O., Kamboh M.I., Tsai S.J., Matsushita S., Nacmias B., Comings D.E., Arboleda H., Ingelsson M., Hyman B.T., Akatsu H., Grupe A., Nishimura A.L., Zatz M., Mattila K.M., Rinne J.O., Goto Y., Asada T., Nakamura S., Kunugi H. Sexually dimorphic effect of the val66met polymorphism of BDNF on susceptibility to Alzheimer's disease: new data and meta-analysis. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2010, 153B:235-242.
17. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J.Neurosci. 2007, 27:2628-2635.
18. Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J.Neurosci. 2003, 23:6690-6694.
19. Harris S.E., Fox H., Wright A.F., Hayward C., Starr J.M., Whalley L.J., Deary I.J. The brain-derived neurotrophic factor val66met polymorphism is associated with age-related change in reasoning skills. Mol. Psychiatry 2006, 11:505-513.
20. Intlekofer, K.A., Cotman, C.W. Exercise counteracts declining hippocampal function in aging and Alzheimer's disease. Neurobiol. Dis. epub ahead of print. http://dx.doi.org/10.1016/j.nbd.2012.06.011.
21. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
22. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M.W., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365. Alzheimer's Disease Neuroimaging Initiative.
23. Lee S.T., Chu K., Jung K.H., Kim J.H., Huh J.Y., Yoon H., Park D.K., Lim J.Y., Kim J.M., Jeon D., Ryu H., Lee S.K., Kim M., Roh J.K. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann. Neurol. 2012, 72:269-277.
24. Lim Y.Y., Ellis K.A., Pietrzak R.H., Ames D., Darby D., Harrington K., Martins R.N., Masters C.L., Rowe C., Savage G., Szoeke C., Villemagne V.L., Maruff P. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012, 79:1645-1652. AIBL Research Group.
25. Masters C.L., Selkoe D.J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer Disease. The Biology of Alzheimer Disease 2012, 181-204. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. D.J. Selkoe, E. Mandelkow, D.M. Holtzman (Eds.).
26. Matsushita S., Arai H., Matsui T., Yuzuriha T., Urakami K., Masaki T., Higuchi S. Brain-derived neurotrophic factor gene polymorphisms and sporadic Alzheimer's disease. J.Neur. Transm. 2005, 112:703-771.
27. Nagata T., Shinagawa S., Nukariya K., Yamada H., Nakayama K. Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement. Geriatr. Cogn. Disord. 2012, 33:266-272.
28. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the preclinical stages of Alzheimer's disease. J.Neurochem. 2005, 93:1412-1421.
29. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging. Neurobiol. Aging 2010, 31:1275-1283.
30. Sambataro F., Murty V.P., Lemaitre H.S., Reed J.D., Das S., Goldberg T.E., Callicott J.H., Weinberger D.R., Mattay V.S. BDNF modulates normal human hippocampal ageing. Mol. Psychiatry 2010, 15:116-118.
31. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011, 7:280-292.
32. Ventriglia M., Bocchio Chiavetto L., Benussi L., Binetti G., Zanetti O., Riva M.A., Gennarelli M. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol. Psychiatry 2002, 7:136-137.
33. Villain N., Chételat G., Grassiot B., Bourgeat P., Jones G., Ellis K.A., Ames D., Martins R.N., Eustache F., Salvado O., Masters C.L., Rowe C.C., Villemagne V.L. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012, 135:2126-2139. AIBL Research Group, [e-pub ahead of print].
34. Villemagne V.L., Pike K.E., Chételat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
35. Voineskos A.N., Lerch J.P., Felsky D., Shaikh S., Rajji T.K., Miranda D., Lobaugh N.J., Mulsant B.H., Pollock B.G., Kennedy J.L. The brain-derived neurotrophic factor val66met polymorphism and prediction of neural risk for Alzheimer disease. Arch. Gen. Psychiatry 2011, 68:198-206.
36. Xu C.L., Wang Z.H., Fan M., Liu B., Song M., Zhen X.T., Jiang T.Z. Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. Mol. Neurosci. 2010, 21:802-807. Alzheimer's Disease Neuroimaging Initiative.